Floatz logo

SOLIFENACIN

Over-Active Bladder

Advanced Research NetworkSmall moleculePhase 4 / ApprovedDormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Over-Active Bladder cohort.

Asset / SponsorPhaseRating
Mirabegron
VA Office of Research and Development
Phase 4BB
TROSPIUM
Allergan
Phase 4BB
Nabiximols
Jazz Pharmaceuticals
Phase 3BB
SOLIFENACIN
VA Office of Research and Development
Phase 4B
Oxybutynin
University of California, Davis
Phase 3B

View all 22 →

Same molecule, other indications

SOLIFENACIN is also rated in:

overactive bladderDormant
B
Indicative ·
62 / 100
View asset →
cognitive disorderDormant
B
Indicative ·
58 / 100
View asset →
Spinal Cord DiseasesDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →